首页> 外文期刊>Gastroenterology research and practice >A Methodological and Reporting Quality Assessment of Systematic Reviews/Meta-Analyses about Chinese Medical Treatment for Gastroesophageal Reflux Disease
【24h】

A Methodological and Reporting Quality Assessment of Systematic Reviews/Meta-Analyses about Chinese Medical Treatment for Gastroesophageal Reflux Disease

机译:关于胃食管反流疾病中医治疗的系统评价/荟萃分析的方法论和报告质量评估

获取原文
       

摘要

Objective. To access the methodological and reporting quality of systematic reviews (SRs)/meta-analyses (MAs) about Chinese medical treatment for gastroesophageal reflux disease (GERD). Methods. The PubMed, Wanfang Data, China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), Chinese Biomedical (CBM), Web of Science, and Cochrane Library databases were searched from inception to June 2020. Two researchers independently screened the literature considering the eligibility criteria. Overview Quality Assessment Questionnaire (OQAQ), Assessment of Multiple Systematic Reviews 2 (AMSTAR 2), and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to assess the methodological and reporting quality of the included reports. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to evaluate the level of evidence in each report. Results. Thirty-three SRs/MAs met the inclusion criteria. The OQAQ results showed that defects in the methodological quality of 17/32 reports were major, with scores of 3 points. Analyzing a single item as the object, search strategies (item 2), and risk of bias in individual studies (item 4) was considered poor. The AMSTAR 2 results showed that 25.4% of the items were not reported, and 7.8% of the items were only partially reported. The overall assessment of AMSTAR 2 showed the majority of systematic reviews and meta-analyses were of low/very low (31/33, 93.9%) methodological quality, with a lack of protocol registration and excluded study list. The PRISMA results showed that 19.9% of items were not reported, and 15.2% of items were only partially reported, due to a lack of protocol registration and study selection methods. The methodological and reporting quality of the included studies was generally poor. Evidence evaluation with GRADE showed that most (31/33) of the included studies had low or very low levels of evidence. Conclusion. The methodological and reporting quality of SRs/MAs about Chinese medical treatment for GERD is generally poor. The main problems included incomplete search strategies, risk of bias in individual studies, the lack of protocol registration and excluded study list, and incorrect study selection methods.
机译:客观的。获取系统评价的方法和报告质量(SRS)/ Meta-Analyses(MAS)关于胃食管反流疾病(GERD)的中医治疗。方法。从20020年6月开始,搜查了PubMed,Wanfang数据,中国国家知识基础设施(CNKI),中国科学和技术期刊数据库(VIP),中国生物医学(CBM),科学版和Cochrane图书馆数据库。两位研究人员独立筛选考虑资格标准的文献。概述质量评估问卷(OQAQ),多次系统评估的评估(AMSTAR 2),以及系统评价和荟萃分析的首选报告项目(PRISMA)指南用于评估所包含的报告的方法和报告质量。建议评估,发展和评估(等级)系统的评分用于评估每份报告中的证据水平。结果。三十三个SRS / MAS符合纳入标准。 OQAQ结果表明,17/32报告的方法论质量的缺陷是主要的,得分为3分。分析单个物品作为对象,搜索策略(第2项)和个人研究中的偏差风险(第4项)被认为是穷人。 AMSTAR 2结果表明,25.4%的物品未报告,只有7.8%的物品仅部分报告。 Amstar 2的总体评估显示,大多数系统评价和荟萃分析低/非常低(31/33,93.9%)方法论质量,缺乏议定书注册和排除的研究名单。 PRISMA结果表明,由于缺乏议定书注册和研究选择方法,仅报告了19.9%的物品,只有15.2%的物品仅部分报告。所纳入研究的方法和报告质量普遍差。以等级的证据评估表明,所包含的研究中的大多数(313/33年)具有较低或非常低的证据。结论。关于中国医学治疗的SRS / MA的方法和报告质量通常是贫困的。主要问题包括不完整的搜查策略,个人研究中偏倚风险,缺乏协议登记和排除的研究清单,以及不正确的学习选择方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号